Overview

Pilot Deprescribing Trials for Beta-blockers in Cardiac Amyloidosis

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators will test the feasibility of N-of-1 trials for deprescribing beta-blockers in patients with Cardiac Amyloidosis. To achieve this objective, 16 N-of-1 trials (on vs. off) will be conducted and subsequently interview participants to better understand feasibility and pragmatism. Each subject can participate in a total of up to 4 periods lasting between 2-6 weeks each based on each patients' health profile. The N-of-1 trials will be iteratively refined in real-time based on feedback.
Phase:
Phase 4
Details
Lead Sponsor:
Weill Medical College of Cornell University
Treatments:
Adrenergic beta-Antagonists